I don't know whether it is 'fake' but it is a pretty meaningless statistic in isolation.
This shows the full extent > 1/3 !! of vaxxine damage. Most people get more sick due to vaxxines than from Covid...And do not forget the 10..15% excess mortality of the vaxxed!
Here you can see the Swiss vaxxination/week https://www.covid19.admin.ch/d…emo=2021-02-07_2022-11-27
Here the Cov-19 mortality :: https://www.covid19.admin.ch/d…Dev=2021-03-29_2022-11-28
The most important peeks after May 2021 all start about 2 weeks after the vaxxination campaigns.
Thus a large chunk of CoV-19 deaths are vaxx induced deaths.
Also seen in excess mortality graph for CH :: https://www.experimental.bfs.a…n/home/projects/momo.html
So this is definit proof that vaxxines killed countless people.
This shows the full extent > 1/3 !! of vaxxine damage. Most people get more sick due to vaxxines than from Covid...And do not forget the 10..15% excess mortality of the vaxxed!
No, it doesn't, but I note your opinion.
Toxic concentrations of chemicals released in the heart may explain myocarditis after COVID-19 vaccine
INDIANAPOLIS (WISH) — According to the Centers for Disease Control and Prevention myocarditis after a COVID-19 vaccine has been reported in adolescents and young adult males within several days after the Pfizer and Moderna shots. It typically occurs after the second dose and usually within a week of vaccination. And now a first of its kind study may explain why this happens.
In a paper published in JAMA Cardiology, scientists at Boston Children’s Hospital looked at 15 children ages 12 to 18 years old who were admitted to the hospital one to nine days after their COVID vaccine. A blood test showed above normal concentrations of the chemical troponin in each patient’s blood. High levels of troponin can lead to damaged heart cells, cell death and heart attacks.
“In this small case series study, myocarditis was diagnosed in children after COVID-19 vaccination, most commonly in boys after the second dose,” authors say in the study. “In this case series, in short-term follow-up, patients were mildly affected. The long-term risks associated with post vaccination myocarditis remain unknown. Larger studies with longer follow-up are needed to inform recommendations for COVID-19 vaccination in this population.”
Incidence rate data show approximately two people per 100,000 will get myocarditis after their COVID shot.
This shows the full extent > 1/3 !! of vaxxine damage. Most people get more sick due to vaxxines than from Covid...And do not forget the 10..15% excess mortality of the vaxxed!
The suppression of compensation/reliability was one puzzle stone the free masons/rotary/XX-finance mafia needed to rob out the world with a fake drug that never has been adequately tested.
Only good news: Also mafia members are affected :: https://www.srf.ch/news/schwei…n-mit-impf-nebenwirkungen
The vaxxine victims are countless. And 1/3 of all vaxx people damaged means at least 50x more damage as from CoVid-19. Among age < 60 at most 1/1000 had some bad experience with Cov-19. And yes - health care workers are in the group age < 60....
A path out of China’s zero-COVID policy
China is showing signs of easing its strict zero-COVID policy after an unusual outbreak of protests against strict lockdowns, mass testing, quarantining and travel restrictions. But loosening health protections carries the risk of a wave of deaths and severe disease. To minimize these, researchers recommend that China ramp up vaccination rates, stockpile antiviral drugs and focus on policies that free medical resources to treat the sickest people.
New Ultrasound Study Shows Increased Liver Stiffness 10 Months After COVID-19 Infection
The retrospective study involving the use of ultrasound shear wave elastography showed a significant increase in liver stiffness 44 weeks after the diagnosis of COVID-19 in comparison to pre-pandemic and pandemic controls.
New research with ultrasound shear wave elastography (SWE) suggests that liver stiffness, a marker of fibrosis, increases in patients with a history of COVID-19 infection, according to a study presented at the Radiological Society of North America (RSNA) 2022 Annual Meeting.
“Our study is part of emerging evidence that COVID-19 infection may lead to liver injury that lasts well after the acute illness,” said Firouzeh Heidari, M.D., a post-doctorate research fellow at Massachusetts General Hospital in Boston.
Elevated transaminases in patients with COVID-19 suggest the presence of liver injury during acute infection, but whether this liver injury leads to lasting liver damage remains unknown. To identify lasting hepatic injury, Dr. Heidari and colleagues compared liver stiffness on ultrasound SWE in patients with a history of COVID-19 infection to that of healthy controls
Vitamin D supplementation in patients with nonalcoholic fatty liver disease: A randomized controlled trial
https://onlinelibrary.wiley.com/doi/10.1002/jgh3.12010
Effect and mechanism of vitamin D activation disorder on liver fibrosis in biliary atresia
It's still recommended, get this, it might work better later in the season. Unbelievable!!!
2021-2022 Interim Flu Vaccine Effectiveness an Abysmal 16%: CDC Study
How effective are flu shots? This was a question few people asked in the popular business and science news culture just a few years ago; however, with the advent of the COVID-19 pandemic vaccine effectiveness takes on a whole new meaning. The annual influenza or flu vaccine (flu shot) is on the Centers for Disease Control and Prevention (CDC) vaccine recommendation list, typically for “all persons aged 6 months of age and older....with rare exception.” This vaccine can be mandated by primary schools, universities, healthcare institutions and many other places of work. But how effective is this medicinal procedure? If young children are forced into getting the vaccine, there should be an assurance, of course, that the vaccine is, of course, safe but also effective. What follows is a breakdown of a CDC report earlier this year that estimates effectiveness rates.
Led by corresponding author Jessica R. Chung, MPH, along with a large team from the CDC, the study titled “Interim Estimates of 2021-2022 Seasonal Influenza Vaccine Effectiveness—United States, February 2022” established the national public health agency’s estimations of currently available flu shots designed to protect against the following influenzas:
A(H1N1)pdm09 (the 2009 pandemic virus)
A(H3N2)
B/Victoria lineage
B/Yamagata lineage
At the time of the report a majority of influenza viruses identified were the A(H3N2) variety. Importantly CDC has estimated the effectiveness of seasonal influenza vaccine at preventing laboratory-confirmed, mild/moderate (outpatient) medically attended acute respiratory infection (ARI) each season since 2004–05 but not this past season due to COVID-19.
Summary
This particular report was based on the data associated with 3,636 children and adults with acute respiratory infection (ARI) enrolled in the U.S. Influenza Vaccine Effectiveness Network during October 4, 2021–February 12, 2022. The CDC reports the results for this period:
“Overall, vaccine effectiveness (VE) against medically attended outpatient ARI associated with influenza A(H3N2) virus was 16% (95% CI = −16% to 39%), which is considered not statistically significant.”
According to the CDC, for this period, the flu vaccine failed to reduce the risk of outpatient medically attended illness with the A(H3N2) virus for the season. As enrollment was weak, the CDC declared that they didn’t have reliable sufficient VE estimates by various cohorts (age, type of product), etc.
How did the CDC derive estimates?
The CDC used seven (7) study sites—part of the agency’s U.S. Influenza Vaccine Effectiveness Network, which includes sites within the following states:
California
Michigan
Pennsylvania
Tennessee
Texas
Washington
Wisconsin
The designated CDC-affiliated sites in these states prospectively enrolled patients aged ≥6 months who had ARI with cough, fever or feverishness, or loss of taste or smell seeking outpatient medical care (i.e., telehealth, primary care, urgent care, or emergency department) or clinical testing for SARS-CoV-2 ≤10 days after illness onset.
Inclusion criteria included age ≥6 months on September 1, 2021, enrollment after local influenza circulation was identified and no treatment with an influenza antiviral medication (e.g., oseltamivir or baloxavir) during this illness.
Applying informed consent, CDC reports that the participants or their guardians were interviewed to collect demographic data, information on general and current health status and symptoms, and 2021–22 influenza vaccination status.
Acknowledgment for This Cohort
In the study discussion, the CDC reports that during the interim period 2021-22 the “VE suggests that influenza did not significantly reduce the risk of outpatient medically attended illness with influenza A(H3N2) viruses that have predominated so far this season. These findings are consistent with previous evidence of low to no protection against outpatient infection with A(H3N2) subclade 2a.2 viruses from an investigation of an influenza outbreak on a university campus during October–November 2021.”
The CDC reports that the findings “underscore the need for ongoing diagnostic testing for influenza, influenza antiviral treatment and prophylaxis when indicated, and everyday preventive measures.”
Given VE is so low, why does CDC still recommend flu vaccination?
The CDC declares that “a growing body of evidence suggests that influenza vaccination can avert serious outcomes, including hospitalization, ICU admission, and death, among persons who are vaccinated but still become infected” even though the VE against the outpatient illness is reduced (and this measures against severe illness).
The agency continues that also “Vaccination likely to prevent illness or serious complications of infection with other influenza viruses that might circulate later in the season, including influenza A(H1N1)pdm09 and B viruses.”
Influence of COVID-19?
The CDC reminds the reader that this particular vaccine effectiveness estimate (VW) was the first such study done since the 2019-20 flu season. This was, of course, due to the pandemic and a historically low circulating influenza pathogen.
Lead Research/Investigator
Jessica R. Chung, MPH, Epidemiologist
Call to Action: TrialSite will be tracking influenza and other vaccine effectiveness rate studies moving forward for breakdown and popular presentation. See the CDC’s report.
Will Swiss court action over vaccine injuries turn the worldwide tide?
Criminal charges have been filed against the Swiss drugs authority on behalf of six people allegedly injured by the Covid vaccination. A team of lawyers and scientists has compiled a comprehensive evidence report and around 1,200 pieces of evidence and made accessible (PDF), arguing that Swissmedic has created a risk to public health which significantly exceeds that of SARS-CoV-2.
Can Near Infrared Light Therapy Help Treat Long COVID? Some Health Professionals Think So
While not in the majority, a band of front-line doctors has been in the trenches responding to the COVID-19 pandemic seeking patient-first regimens based on repurposed drugs and other non-pharmaceutical interventions with an aim of saving more lives and reducing the suffering among a growing long COVID patient population. Controversial in an age of top-down, national protocol-driven medicine, doctors advocating for alternative points of view in some cases have paid with their licenses. The medical industry shouldn’t be proud of its COVID-19 response strategy. With over a million deaths, America, the biggest, richest economy with the most sophisticated health system, records the greatest number of COVID-19 deaths. Long Covid patients, potentially representing anywhere from 10%-30% of all COVID-19 cases, suffer with no formal protocols established nationally nor any medications authorized specifically for that purpose. While the National Institutes of Health (NIH) did allocate over $1 billion for long COVID research, this started way back in February 2021 and has yet to deliver any real goods. A growing chasm between academic medicine, health systems, and the pain and suffering on the street due to long COVID sends patients out looking for alternative pharmaceutical and non-pharmaceutical interventions. While some commercially-minded groups are exploiting these patients with all sorts of snake oil products, other well-intentioned, passionate, and non-commercial physicians are at the forefront of real-world medicine and the unfolding science, such as the physicians at the Front Line COVID-19 Critical Care (FLCCC) Alliance, who have raised controversy by prescribing off label various regimen combinations, including ivermectin and now also near-infrared light therapy for long COVID. But is there medical evidence for the use of near-infrared light therapy targeting long COVID?
According to one definition, near-infrared light therapy uses directional low-power but high-fluency light, monochromatic or quasimonochromatic, from lasers or light-emitting diodes (LEDs) in the wavelengths, red to near-infrared, to mediate biological functions or to promote therapeutic effects in a safe way. See the report from the International Journal of Medical Sciences.
This class of light therapy falls under the umbrella of a class of products called photo-biomodulation therapy or “PBMT.”
One recent assessment of potential benefits derives from a Chinese study led by Hua Zhong, Department of Ophthalmology at the First Affiliated Hospital of Kunming, Medical University.
What is the difference between light therapy and near-infrared therapy?
While light therapy involves exposure to light actually brighter than indoor light, often used to treat persons with challenged cognitive ability due to conditions such as depression, seasonal affective disorder, or sleep disorders, this involves light therapy on the visible part of the light spectrum—which equals 400 nm to 480 nm. This differs slightly from color light therapy but has been shown to help patients deal with problems ranging from depressed moods to sleep problems.
While red light therapy also falls into the visible part of the light spectrum (630-700 nm) on the electromagnetic scale, it's used as a regimen against the surface of the skin. But near-infrared wavelengths are actually part of the invisible light spectrum segment (700 and 1200nm).
This means that this method involves longer wavelengths with deeper penetration, which purportedly delivers energy to cells that can stimulate not only healing but also lower pain levels. This approach becomes more granular as different cell and tissue segments may have their own tailored light absorption requirements at different wavelengths. While blue wavelength light may benefit dermatology, other colors and wavelengths may impact other deeper parts of the human body.
Where is near-infrared light used today?
Based on a number of sources cited below, infrared therapy is used widely in medicine, dentistry, and veterinary, as well as for autoimmune diseases.
Some risks are involved, and some mainstream medical experts report that the use of this class of regimen for the treatment of chronic diseases at the expense of not taking prescribed medications or other treatment procedures prescribed could lead to trouble.
Studies
In one case report reported in Brain Stimulation, the study evaluated neuroimaging and cognitive testing on a patient with Post-COVID-19 before and after near infrared therapy. The researchers showed that the use of near-infrared therapy helped a patient with presented neurocognitive executive dysfunction due to COVID-19 “return to normal cognitive functioning.”
Led by the Neurological Associates—the Interventional Group in Los Angeles, the study team concluded that while only a case series, “NIR light therapy may be a promising technique for the treatment of cortical hypoperfusion brought on by COVID-19 infection.” TrialSite reminds the case series of just a patient (or a handful of patients) typically isn’t weighty enough for conclusive evidence.
A more recent relevant study program in Brazil published in “Laser Physics Letters” revealed that various light-based therapies show promising results in helping treat patients with long COVID, including patients with symptoms such as muscle and joint pain, neurological issues, and dermatological damage.
Led by investigators working at the Center for Research in Optics and Photonics (CEPOF) as well as the National Institute of Science and Technology (INCT) in Basic Optics and Optics Applied to Life Sciences—both led by the University of Sao Paulo, Sao Carlos Institute of Physics (IFSC-USP) professor Vanderlei Bagnato—as reported by Agencia FAPESP, researchers sought to develop guidelines to help treat post-COVID-19 complications along with the establishment of novel protocols supported by multidisciplinary teams addressing the mounting long COVID crisis. Their recent article can be found here.
Other recent studies suggest the use of photo-biomodulation therapy (PBMT) of the particular wavelength 1068 nm as a therapeutic regimen targeting COVID-19 may improve conditions based on a handful of findings, including cytoprotection, nitric oxide (NO) release, inflammation changes, improved blood flow, and more.
The authors from Durham University, Department of Biosciences and the QuietMind Foundation in Philadelphia suggest that “PBMT 1068 is a potentially effective and innovative approach for avoiding severe and critical illness in COVID-19 patients, although further clinical evidence is required.”
The prominent YouTube doctor, Dr. Mobeen Syed, also affiliated with the FLCCC, recently presented that near-infrared light may help to protect neurons by reestablishing mitochondrial health, referring to a study titled “Protection against neurodegeneration with low-dose methylene blue and near-infrared light” led by F. Gonzalez-Lima and Allison Auchter introduce that both methylene blue and near-infrared light interventions may act by “a cellular mechanism involving enhancement of the electron transport chain in mitochondria.”
The authors affiliated with the University of Texas, Department of Psychology and Institute of Neuroscience wrote at the time (2015), “Low-level near-infrared light applied transcranial deliver photos to cortical neurons that are accepted by cytochrome oxidase, which causes increased cell respiration and cerebral blood flow.”
The Texas-based neurological investigators declared, “Breakthrough in vivo studies with these interventions suggest that targeting mitochondrial respiration may be beneficial for protection against different types of neurodegenerative disorders.” See the FLCCC video presentation.
Earlier on in the pandemic, a trio of researchers from San Diego and Milwaukee published a paper, “Light as a potential treatment for pandemic coronavirus infections: A perspective.”
The authors noted:
“Further evidence shows that blue light inactivates several viruses, including the common flu coronavirus, and that in experimental animals, red and near infrared light reduce respiratory disorders, similar to those complications associated with coronavirus infection. Moreover, in patients, red light has been shown to alleviate chronic obstructive lung disease and bronchial asthma. These findings call for urgent efforts to further explore the clinical value of light, and not wait for another pandemic to serve as a reminder. The ubiquity of inexpensive light emitting lasers and light emitting diodes (LEDs), makes it relatively easy to develop safe low-cost light-based devices with the potential to reduce infections, sanitize equipment, hospital facilities, emergency care vehicles, homes, and the general environment as pilot studies have shown. “
Is PBMT the same as infrared light therapy?
No, but infrared light therapy falls under a subcategory of PBMT, which is an umbrella term classifying several technologies that utilize different light wavelengths. PBMT includes laser and LED technologies emitting varying wavelengths in the visible or near-infrared spectrum. So, therapies like red light therapy are a subset of PBMT. There are dozens of PBMT (again, an umbrella term) studies ongoing, with a few targeting COVID—and none targeting long COVID that TrialSite could find.
What’s the clinical trial pipeline?
TrialSite reviewed the American clinical trials registry to evaluate any ongoing clinical trials involving near-infrared light therapy or PBMT targeting long COVID.
A search using the term “near-infrared light therapy” turns up 85 active studies in the Clinicaltrials.gov registry. Many of them are hybrid in that they may also involve photo-biomodulation and other technologies. The therapeutic targets range from chronic pain and other forms of pain to aging, Alzheimer’s, and Parkinson’s to many more conditions. Only three COVID-related studies are listed but are not relevant for the purposes of this investigation. None targeted long COVID. And the vast majority of these therapeutic areas are not proven.
Similarly, for the term PBMT, the search found four ongoing studies, of which none target long COVID.
Conclusion from FLCCC
Although there is no evidence as would be defined and accepted by the medical establishment for the use of infrared light therapy targeting long COVID TrialSite estimates that there may be as many as 20 million people in America suffering from this condition. In some cases, this group is debilitated and in desperate condition.
While academic medicine will crawl along attempting to develop evidence, groups of physicians will attempt to advance real-world regimens based on a confluence of possible evidentiary sources. While not strong enough for the FDA, NIH, or CDC, with informed consent, off-label usage of therapies deemed safe by physicians continues to grow in commonality.
The FLCCC uses this light therapy in its vaccine injury protocol called “I-RECOVER post vaccine.”
The FLCCC recognizes that “major public health authorities do not recognize post-COVID-vaccine injuries and no specific ICD classification code exists for the disease.”
The group continues, “Since there are no published reports detailing how to manage vaccine-injured patients, our treatment approach is based on the postulated pathogenetic mechanism, clinical observation, and patient anecdotes.” They continue on with individualized treatments targeting each patient’s “presenting symptoms and disease syndromes” they recognize that “chances are, not all patients will respond equally to the same intervention.” Emphasizing early treatment, the FLCCC includes “Sunlight and Photo-biomodulation (PBM) therapy, also referred to as “low-level light therapy, red light therapy and near-infrared light therapy.” Again, the PBM represents the umbrella category per previously reported.
The FLCCC recommends:
“Of all the wavelengths of sunlight, near-infrared radiation (NIR-A) has the deepest penetration into tissues. NIR-A in the range of 1000 to 1500 nm is optimal for heating tissues. For more detailed information see ‘An Approach to the Management of Post-Vaccine Syndrome.”
The group’s “I-RECOVER: Long COVID” doesn’t include near-infrared light (or other PBM) therapies.
TrialSite’s founder Daniel O’Connor got in touch with Dr. Paul Marik, one of the FLCCC founders and well-known researcher—controversial from the mainstream perspective due to what he calls a “Big Pharma-driven agenda to monetize the pandemic.”
Dr. Paul Marik
Source: FLCCC
Dr. Marik reports:
“We have patients that are seeing remarkable results from the combination of Methylene Blue and PBMT (again includes near-infrared light therapy). Working synergically together, there is solid science backing the use of these approaches.”
Marik didn’t claim that it was a proven, authorized treatment but rather that he and his colleagues are observing a significant number of improved patients with this off-label regimen.
For example, one study shows that near infrared therapy relieves TLR-4 dependent hyper-inflammation of the type induced by COVID-19.” See a study led by corresponding authors Margaret Ahmad and Nathalie Jourdan, both at Sorbonne University in Paris.
Dr. Marik is a wealth of information and informed TrialSite’s O’Connor that some of this evidence dates back to the Surgeon General of Massachusetts in the 1918 influenza pandemic known as the “Open-Air” treatment. See the link for a summary.
According to Marik, “Mortality declined in this study from 40% down to 10%, which was highly significant.” The physician-investigator pointed out that infrared can penetrate the skin at deeper levels leading to benefits including improvement of mitochondrial function leading to improved cellular ATP offering health benefits.
A review of various medical academic papers points to multiple examples of preclinical work backing such claims in animal research. In 2008, a basic science paper purported that low-intensity light therapy associates with mitochondrial photostimulation and boosted APT production, leading to greater transient increases in reactive oxygen species (ROS). In that same study by Tafur et al., Karu reports on experiments that show a specific wavelength of UVA light, such as red and infrared “can lead to activation of mitochondrial oxygen consumption.”
Other studies reveal that persons who are sun-averse face higher mortality conditions. One prominent study is from Karolinska University Hospital, Stockholm, titled “Avoidance of sun exposure is a risk factor for all-cause mortality: results from the Melanoma in Southern Sweden cohort.” Of course, factors such as the social determinants of health could be a contributing factor for such a result.
What about Big Pharma? Marik told TrialSite’s founder, “Frankly, I think all of us, with our eyes wide open, saw the inherent bias toward Big Pharma commercialization during the pandemic.” TrialSite can confirm a significant bias chronicled from NIH ACTIV research to the over hundred billion two COVID-19 vaccine producers are generating for a vaccine product that wanes in effectiveness within a few months. See, for example, “Therapeutic Management of Patients with COVID-19: Some Unanswered Questions about Disturbing Chasm.” For a description of how the NIH Foundation managed ACTIV during the pandemic, see the following. We also encourage a read of “Big Money, Politics & Fed Gov Redirects & Captivates Mass Attention, Obscuring Pragmatic Off-Label Studies Targeting COVID-19.”
“My eyes are wide open, and I am a new person after this experience.” Marik continued, “Unless Big Pharma can find a way to charge us for licenses to sunlight and low-cost forms of treatment regimen, they aren’t interested in that kind of healthcare.” Unfortunately, this may not be conducive to widespread health as Big Pharma’s expertise is needed to develop, produce and distribute drugs—even lower-cost generic regimen
Unfortunately, no federal agency charged with overseeing aspects of healthcare, whether the FDA, NIH, or CDC, seem that interested in opening up the collective mind to consider a different pathway. Perhaps the monetization pressures across society are too great?
https://www.ncbi.nlm.nih.gov/p…(also%20reviewed%20in%205)
Scientist who worked at Wuhan lab claims Covid-19 was man-made by the U.S.
Epidemiologyst Andrew Huff has some wild claims about the Wuhan lab in China
The official version handled by most mainstream media outlets is that the Covid-19 virus originated from a wet market in the city of Wuhan, China. It reportedly came from dead meat of either a bat or a pangolin, but there are many emerging inconsistencies in this version of the story. In a recent book called 'The Truth about Wuhan' written by epidemiologist Adrew Huff, there is a scandalous claim that has been considered a conspiracy theory for the last two years. According to Huff, the virus was man-made but there is another revelation that will make heads turn.
Andrew Huff worked at one of Wuhan's labs where they experimented with different dangerous pathogens. He used to work at a non-profit that studied viruses and blames the American government for creating the virus. According to Huff, Covid-19 leaked from the Wuhan Institute of Virology in China. He claims to have been there when the American government was funding the study and creation of many viruses but they didn't have the best security inside the premises when he was there. Mounting evidence keeps making this story more intriguing by the minute, evidence suggests Huff could be telling the truth
Can Near Infrared Light Therapy Help Treat Long COVID?
There are only three (3) known active light frequencies that are supporting cell live. The near infra read is the 832nm band that helps the mitochondria to survive by pumping energy into the ADP cycle. LASER just can treat the skin and near skin area. But Medlouxx can reach much deeper regions. (http://www.medlouxx.com/) I use it since some years for regenerating eye tissue.
The high energy band is used to kill cells... and the medium band more or less for thermal stimulation.
React19 Research: The Spike Protein Problem
Part 1: Spike Protein Lit Review
1st indicator that the spike protein was a problem is by looking at the vaccine adverse reaction literature. See attached, over 1300 articles. What you notice by reviewing these articles is that all the vaccines seem to have the same side effect profile. For example, myocarditis has been reported for both J&J and also AstraZeneca. Another example, the vaccine induced thrombotic thrombocytopenia that paused the J&J roll out in the US, which is unique in that it has positive PF4 antibodies without the patient being exposed to heparin, has also been described in the mRNA vaccines. These vaccines use different technology but the common theme among them is the spike protein.
There are only three (3) known active light frequencies that are supporting cell live. The near infra read is the 832nm band that helps the mitochondria to survive by pumping energy into the ADP cycle. LASER just can treat the skin and near skin area. But Medlouxx can reach much deeper regions. (http://www.medlouxx.com/) I use it since some years for regenerating eye tissue.
The high energy band is used to kill cells... and the medium band more or less for thermal stimulation.
Interesting that you use this type of treatment for your eyes. Researchers are looking at retina damage as a Way to detect long COVID.
Eyes on PCS - Analysis of the Retinal Microvasculature in Patients With Post-COVID-19 Syndrome
"retina damage as a Way to detect long COVID.
Sorting out the inflammatory retinal damage due to the "natural" Covid as opposed to the Pfizer and other flavors
should be interesting..
" An association between AMN and both COVID-19 infection and vaccination raises the question as to whether a common immune-mediated pathway can trigger this peculiar macular disease.
"German photographs"....a euphemism for the youtube censors..
=" Lethal Vaccine-induced Myocarditis"
Adipose tissue in COVID-19: detection of SARS-CoV-2 in adipocytes and activation of the interferon-alpha response
https://www.ncbi.nlm.nih.gov/p…COVID,of%20SARS%2DCoV%2D2.
Abstract
Objective
Obesity is a recognized risk factor for the progression to severe forms of COVID-19, yet the mechanisms of the association are unclear.
Methods
Subcutaneous abdominal adipose tissue specimens of subjects deceased from COVID-19 (n = 23) were compared to those of controls dying abruptly from causes other than infectious (accidental trauma, sudden cardiac death). Alterations of lung parenchyma consistent with moderate to severe disease were detected in all COVID-19 cases, not in controls. Investigations included: histopathologic features, detection of virus antigens and genome, characterization of infiltrating leukocytes, transcription levels of immune-related genes. Results
By RT-PCR, the SARS-CoV-2 genome was detected in the adipose tissue of 13/23 (56%) cases of the COVID-19 cohort. The virus nucleocapsid antigen was detected in the cytoplasm of 1–5% adipocytes in 12/12 COVID-19 cases that were virus-positive by PCR in the adipose tissue (one case could not be assessed due insufficient tissue). The adipose tissue of COVID-19 cases showed leukocyte infiltrates and upregulation of the interferon-alpha pathway. After adjusting for age and sex the activation score of IFN-alpha was directly related with transcription levels of the ACE2 gene, a key entry factor of SARS-CoV-2.
Conclusions
In lethal COVID-19 cases, the SARS-CoV-2 nucleocapsid antigen has been detected in a sizeable proportion of adipocytes, showing that the virus may directly infect the parenchymal cells of subcutaneous fat. Infection appears to activate the IFN alpha pathway and to attract infiltrating leukocytes. Due to the huge numbers of adipocytes in adults, the adipose tissue represents a significant reservoir for SARS-CoV-2 and an important source of inflammatory mediators.
The Action of Vitamin D in Adipose Tissue: Is There the Link between Vitamin D Deficiency and Adipose Tissue-Related Metabolic Disorders?
Conclusions
The current review presents the effect of vitamin D on adipose tissue and its clinical significance. The literature data indicate that the active form of vitamin D is produced, stored, and degraded in adipose tissue. Moreover, both VDR and 1,25D-MARRS are expressed in adipocytes, allowing vitamin D to exert a genomic and nongenomic response in adipose tissue. Vitamin D exerts an effect on adipogenesis, apoptosis, oxidative stress, inflammation, the secretion of adipocytokines, lipid metabolism, and thermogenesis, as presented in Figure 5. Thus, it contributes to the maintenance of adipose tissue structure, function, and fat content. Therefore, it is worth speculating that vitamin D supplementation may be a promising means of improving the dysfunctional adipose tissue found in T2DM and obesity. However, further clinical studies are needed to establish the benefits of vitamin D supplementation in subjects with varying levels of severity of metabolic disorders and obesity.
Changes in SpO2 on Room Air for 34 Severe COVID-19 Patients after Ivermectin-Based Combination Treatment: 62% Normalization within 24 Hours
Abstract
The emergence of COVID-19 in March 2020 challenged Zimbabwe to respond with limited medical facilities and therapeutic options. Based on early clinical indications of efficacy for the macrocyclic lactone, Ivermectin (IVM), against COVID-19, IVM-based combination treatments were deployed to treat it. Oxygen saturation (SpO2) data were retrospectively analyzed for 34 severe, hypoxic COVID-19 patients all on room air (without supplemental oxygen). The patients, median age 56.5, were treated at clinics or at home between August 2020 and May 2021. All but three of these 34 patients had significantly increased SpO2 values within 24 h after the first IVM dose. The mean increase in SpO2 as a percentage of full normalization to SpO2 = 97 was 55.1% at +12 h and 62.3% at +24 h after the first IVM dose (paired t-test, p < 0.0000001). These results parallel similar sharp, rapid increases in SpO2, all on room air, for 24 mostly severe COVID-19 patients in the USA (California) who were given an IVM-based combination treatment. All patients in both of these critical series recovered. These rapid increases in SpO2 values after IVM treatment stand in sharp contrast to declines in SpO2 and associated pulmonary function through the second week following the onset of moderate or severe COVID-19 symptoms under standard care.
FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2
FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2 - Nature
Abstract
Prevention of SARS-CoV-2 infection through the modulation of viral host receptors, such as ACE21, could represent a new chemoprophylactic approach for COVID-19 complementing vaccination2,3. However, the mechanisms controlling ACE2 expression remain elusive. Here, we identify the farnesoid X receptor (FXR) as a direct regulator of ACE2 transcription in multiple COVID19-affected tissues, including the gastrointestinal and respiratory systems. We then use the over-the-counter compound z-guggulsterone (ZGG) and the off-patent drug ursodeoxycholic acid (UDCA) to reduce FXR signalling and downregulate ACE2 in human lung, cholangiocyte and intestinal organoids and in the corresponding tissues in mice and hamsters. We demonstrate that UDCA-mediated ACE2 downregulation reduces susceptibility to SARS-CoV-2 infection in vitro, in vivo and in human lungs and livers perfused ex situ. Furthermore, we illustrate that UDCA reduces ACE2 expression in the nasal epithelium in humans. Finally, we identify a correlation between UDCA treatment and positive clinical outcomes following SARS-CoV-2 infection using retrospective registry data, and confirm these findings in an independent validation cohort of liver transplant recipients. In conclusion, we identify a novel function of FXR in controlling ACE2 expression and provide evidence that modulation of this pathway could be beneficial for reducing SARS-CoV-2 infection, paving the road for future clinical trials.
Effect of ursodeoxycholic acid for reducing the deficit of vitamin D status and bone mineral density at gallstones]
https://pubmed.ncbi.nlm.nih.go…to%20prevent%20osteopenia.
Abstract
Aim: To study the effect of ursodeoxycholic acid on vitamin D levels and bone mineral density (BMD) in patients with gallstone disease (GSD).
Materials and methods: BMD assessed by dual-energy X-ray densitometry in 53 patients with gallstone disease, of whom 21 patients received litolitic therapy at a daily dose of 10 mg/kg for 1,5-2 years. The control group consisted of 15 persons matched by sex and age.
Results: Patients with gallstone disease treated with UDCA (ursosan), vitamin D deficiency was found in 5%, and in patient that didn't receive litolitic therapy--in 69% of cases.
Conclusion: Ursotherapy in patients with gallstone disease reduces vitamin D deficiency and is an effective measure to prevent osteopenia.
